BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 28945877)

  • 1. Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review.
    García-Foncillas J; Alba E; Aranda E; Díaz-Rubio E; López-López R; Tabernero J; Vivancos A
    Ann Oncol; 2017 Dec; 28(12):2943-2949. PubMed ID: 28945877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review.
    Vymetalkova V; Cervena K; Bartu L; Vodicka P
    Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer.
    García-Foncillas J; Tabernero J; Élez E; Aranda E; Benavides M; Camps C; Jantus-Lewintre E; López R; Muinelo-Romay L; Montagut C; Antón A; López G; Díaz-Rubio E; Rojo F; Vivancos A
    Br J Cancer; 2018 Dec; 119(12):1464-1470. PubMed ID: 30467411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Circulating Tumor DNA (ctDNA) Detection Using BEAMing and Its Clinical Significance.].
    Nakamura K
    Rinsho Byori; 2016 May; 64(4):400-406. PubMed ID: 29182806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of circulating tumor DNA in the management of patients with colorectal cancer.
    Moati E; Taly V; Didelot A; Perkins G; Blons H; Taieb J; Laurent-Puig P; Zaanan A
    Clin Res Hepatol Gastroenterol; 2018 Oct; 42(5):396-402. PubMed ID: 29627453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.
    Normanno N; Esposito Abate R; Lambiase M; Forgione L; Cardone C; Iannaccone A; Sacco A; Rachiglio AM; Martinelli E; Rizzi D; Pisconti S; Biglietto M; Bordonaro R; Troiani T; Latiano TP; Giuliani F; Leo S; Rinaldi A; Maiello E; Ciardiello F;
    Ann Oncol; 2018 Jan; 29(1):112-118. PubMed ID: 28950295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer.
    Bando H; Kagawa Y; Kato T; Akagi K; Denda T; Nishina T; Komatsu Y; Oki E; Kudo T; Kumamoto H; Yamanaka T; Yoshino T
    Br J Cancer; 2019 May; 120(10):982-986. PubMed ID: 31015557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of liquid biopsies in colorectal cancer.
    Wills B; Gorse E; Lee V
    Curr Probl Cancer; 2018 Nov; 42(6):593-600. PubMed ID: 30268335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid biopsy challenge and hope in colorectal cancer.
    Burz C; Rosca A; Pop VV; Buiga R; Aldea C; Samasca G; Silaghi C; Sur D; Lupan I; Pricopie A
    Expert Rev Mol Diagn; 2019 Apr; 19(4):341-348. PubMed ID: 30943811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer.
    Benavides M; Alcaide-Garcia J; Torres E; Gil-Calle S; Sevilla I; Wolman R; Durán G; Álvarez M; Reyna-Fortes C; Ales I; Pereda T; Robles M; Kushnir M; Odegaard J; Faull I; Alba E
    ESMO Open; 2022 Jun; 7(3):100481. PubMed ID: 35525184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer.
    Siena S; Sartore-Bianchi A; Garcia-Carbonero R; Karthaus M; Smith D; Tabernero J; Van Cutsem E; Guan X; Boedigheimer M; Ang A; Twomey B; Bach BA; Jung AS; Bardelli A
    Ann Oncol; 2018 Jan; 29(1):119-126. PubMed ID: 28945848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liquid Biopsies in Colorectal Cancer: Monitoring Genetic Heterogeneity.
    Gargalionis AN; Papavassiliou AG
    Trends Cancer; 2017 Mar; 3(3):166-168. PubMed ID: 28718430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profiling Colorectal Cancer in the Landscape Personalized Testing-Advantages of Liquid Biopsy.
    Verbanac D; Čeri A; Hlapčić I; Shakibaei M; Brockmueller A; Krušlin B; Ljubičić N; Baršić N; Detel D; Batičić L; Rumora L; Somborac-Bačura A; Štefanović M; Ćelap I; Demirović A; Petlevski R; Petrik J; Grdić Rajković M; Hulina-Tomašković A; Rako I; Saso L; Barišić K
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios.
    Normanno N; Cervantes A; Ciardiello F; De Luca A; Pinto C
    Cancer Treat Rev; 2018 Nov; 70():1-8. PubMed ID: 30053724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical utility versus futility: a tipping point for liquid biopsies in bladder cancer.
    Kouba E; Cheng L
    Future Oncol; 2019 Nov; 15(33):3751-3753. PubMed ID: 31651200
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of Emergent Circulating Tumor DNA
    Kim TW; Peeters M; Thomas A; Gibbs P; Hool K; Zhang J; Ang AL; Bach BA; Price T
    Clin Cancer Res; 2018 Nov; 24(22):5602-5609. PubMed ID: 29898991
    [No Abstract]   [Full Text] [Related]  

  • 18. Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Spindler KG; Boysen AK; Pallisgård N; Johansen JS; Tabernero J; Sørensen MM; Jensen BV; Hansen TF; Sefrioui D; Andersen RF; Brandslund I; Jakobsen A
    Oncologist; 2017 Sep; 22(9):1049-1055. PubMed ID: 28778958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA.
    Patelli G; Vaghi C; Tosi F; Mauri G; Amatu A; Massihnia D; Ghezzi S; Bonazzina E; Bencardino K; Cerea G; Siena S; Sartore-Bianchi A
    Target Oncol; 2021 May; 16(3):309-324. PubMed ID: 33738696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of cell-free DNA in predicting colorectal cancer prognosis.
    Cao B; Zhou X; Yang W; Ma J; Zhou W; Fan D; Hong L
    Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):39-48. PubMed ID: 28838275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.